Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application
| العنوان: | Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application |
|---|---|
| المؤلفون: | Naga Rajiv Lakkaniga, Wei Yan, Naresh Gunaganti, Francesca Carlomagno, Neil Q. McDonald, Massimo Santoro, Fengping Lv, Hong-yu Li, Brendan Frett |
| المساهمون: | Yan, Wei, Lakkaniga, Naga Rajiv, Carlomagno, Francesca, Santoro, Massimo, Mcdonald, Neil Q., Lv, Fengping, Gunaganti, Naresh, Frett, Brendan, Li, Hong-Yu |
| المصدر: | J Med Chem Journal of medicinal chemistry (Online) 62 (2019): 1731–1760. doi:10.1021/acs.jmedchem.8b01092 info:cnr-pdr/source/autori:Yan W.; Lakkaniga N.R.; Carlomagno F.; Santoro M.; McDonald N.Q.; Lv F.; Gunaganti N.; Frett B.; Li H.-Y./titolo:Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application/doi:10.1021%2Facs.jmedchem.8b01092/rivista:Journal of medicinal chemistry (Online)/anno:2019/pagina_da:1731/pagina_a:1760/intervallo_pagine:1731–1760/volume:62 |
| سنة النشر: | 2018 |
| مصطلحات موضوعية: | animal structures, Antineoplastic Agents, 01 natural sciences, Article, Rats, Sprague-Dawley, 03 medical and health sciences, Catalytic Domain, Cell Line, Tumor, Neoplasms, Drug Discovery, medicine, Animals, Humans, Receptor, trkB, Receptor, trkC, Precision Medicine, Receptor, trkA, Receptor, Protein Kinase Inhibitors, 030304 developmental biology, 0303 health sciences, Mice, Inbred BALB C, Chemistry, Drug discovery, Kinase Family, Kinase, Drug Discovery3003 Pharmaceutical Science, Imatinib, Tropomyosin, Receptor Kinase, (TRK) Inhibitors, Precision medicine, 0104 chemical sciences, enzymes and coenzymes (carbohydrates), 010404 medicinal & biomolecular chemistry, nervous system, Trk receptor, embryonic structures, Cancer research, Molecular Medicine, medicine.drug |
| الوصف: | The use of kinase-directed precision medicine has been heavily pursued since the discovery and development of imatinib. Annually, it is estimated that around ∼20 000 new cases of tropomyosin receptor kinase (TRK) cancers are diagnosed, with the majority of cases exhibiting a TRK genomic rearrangement. In this Perspective, we discuss current development and clinical applications for TRK precision medicine by providing the following: (1) the biological background and significance of the TRK kinase family, (2) a compilation of known TRK inhibitors and analysis of their cocrystal structures, (3) an overview of TRK clinical trials, and (4) future perspectives for drug discovery and development of TRK inhibitors. |
| تدمد: | 1520-4804 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8412387699512bbcc730e78680faf874 https://pubmed.ncbi.nlm.nih.gov/32841014 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....8412387699512bbcc730e78680faf874 |
| قاعدة البيانات: | OpenAIRE |
Find this issue from the American Chemical Society | تدمد: | 15204804 |
|---|